Anygen Co.

South Korea

Anygen Co.

South Korea

Time filter

Source Type

Patent
Anygen Co. | Date: 2017-01-25

The present invention relates to a novel exenatide analogue, which is an exenatide analogue in which the first to fifteenth amino acids from the C-terminal of the amino acid sequence of exenatide are deleted and a fatty acid is conjugated. The present invention provides a short length exenatide exhibiting almost the same level of anti-diabetic effects compared with that of conventional exenatide and liraglutide, which is an anti-diabetic drug, and capable of reducing the preparation cost of exenatide.


Patent
ANYGEN Co. | Date: 2015-03-23

The present invention relates to a novel exenatide analogue, which is an exenatide analogue in which the first to fifteenth amino acids from the C-terminal of the amino acid sequence of exenatide are deleted and a fatty acid is conjugated. The present invention provides a short length exenatide exhibiting almost the same level of anti-diabetic effects compared with that of conventional exenatide and liraglutide, which is an anti-diabetic drug, and capable of reducing the preparation cost of exenatide.


Park M.-H.,Chungnam National University | Lee Y.Y.,Chung - Ang University | Lee Y.Y.,Bio Core Ltd | Cho K.H.,Bio Core Ltd | And 11 more authors.
Biomedical Chromatography | Year: 2016

A liquid chromatography-triple quadrupole mass spectrometric (LC-MS/MS) method was developed and validated for the determination of 5-nitro-5′-hydroxy-indirubin-3′-oxime (AGM-130) in human plasma to support a microdose clinical trial. The method consisted of a liquid-liquid extraction for sample preparation and LC-MS/MS analysis in the positive ion mode using TurboIonSprayTM for analysis. d3-AGM-130 was used as the internal standard. A linear regression (weighted 1/concentration) was used to fit calibration curves over the concentration range of 10-2000 pg/mL for AGM-130. There were no endogenous interference components in the blank human plasma tested. The accuracy at the lower limit of quantitation was 96.6% with a precision (coefficient of variation, CV) of 4.4%. For quality control samples at 30, 160 and 1600 pg/mL, the between run CV was ≤5.0 %. Between-run accuracy ranged from 98.1 to 101.0%. AGM-130 was stable in 50% acetonitrile for 168 h at 4°C and 6 h at room temperature. AGM-130 was also stable in human plasma at room temperature for 6 h and through three freeze-thaw cycles. The variability of selected samples for the incurred sample reanalysis was ≤12.7% when compared with the original sample concentrations. This validated LC-MS/MS method for determination of AGM-130 was used to support a phase 0 microdose clinical trial. © 2016 John Wiley & Sons, Ltd.


Choi S.-J.,Gwangju Institute of Science and Technology | Lee J.-E.,Gwangju Institute of Science and Technology | Jeong S.-Y.,Anygen Co. | Im I.,Gwangju Institute of Science and Technology | And 11 more authors.
Journal of Medicinal Chemistry | Year: 2010

To enhance the ability of indirubin derivatives to inhibit CDK2/cyclin E, a target of anticancer agents, we designed and synthesized a new series of indirubin-3′-oxime derivatives with combined substitutions at the 5 and 5′ positions. A molecular docking study predicted the binding of derivatives with OH or halogen substitutions at the 5′ position to the ATP binding site of CDK2, revealing the critical interactions that may explain the improved CDK2 inhibitory activity of these derivatives. Among the synthesized derivatives, the 5-nitro-5′-hydroxy analogue 3a and the 5-nitro-5′-fluoro analogue 5a displayed potent inhibitory activity against CDK2, with IC50 values of 1.9 and 1.7 nM, respectively. These derivatives also showed antiproliferative activity against several human cancer cell lines, with IC50 values of 0.2-3.3 μM. A representative analogue, 3a, showed greater than 500-fold selectivity for CDK relative to selected kinase panel and potent in vivo anticancer activity. © 2010 American Chemical Society.


Patent
Anygen Inc., Samsung, Snu R&D Foundation and Chonbuk National University | Date: 2016-01-13

The present invention relates to a pharmaceutical composition for treating or preventing erectile dysfunction, containing LDD175 as an active ingredient. Furthermore, the present invention relates to a co-administration preparation for treating or preventing erectile dysfunction, containing LDD175 and a PDE5 inhibitor as active ingredients. The LDD175 of the present invention has an excellent corporal smooth muscle relaxation effect, and thus significantly improved erectile function. Since the LDD175 of the present invention acts on BK_(Ca )channels, and thus is expected to have little adverse cardiovascular effects. The LDD175 of the present invention exhibits an erectile dysfunction therapeutic ability equivalent to that of udenafil, which is a PDE5 inhibitor, and showed a synergistic corporal smooth muscle relaxation effect when being co-administered with udenafil.


Patent
Anygen Co. | Date: 2014-05-23

Provided is a conjugate including a pharmacologically active substance covalently bound to chitosan or its derivative and a method for transmucosal delivery of a pharmacologically active substance using the same. Specifically a conjugate includes a pharmacologically active substance covalently bound via a linker to chitosan; and a pharmaceutical composition for transmucosal administration of a drug includes the aforementioned conjugate and a pharmaceutically acceptable carrier. Further provided is a method for in vivo delivery of a pharmacologically active substance via a transmucosal route, by covalent binding of the active substance with chitosan or its derivative via a linker. The conjugate in accordance with the present invention exhibits excellent absorption rate and biocompatibility in biological mucous membranes, particularly mucous membranes of the alimentary canal (especially the gastrointestinal tract), in vivo degradability, and superior bioavailability even with oral administration, thus enabling treatment of diseases via oral administration of a drug.


The present invention relates to a composition for regulating circadian rhythms, a composition for diagnosing circadian rhythm disorders and a diagnostic kit, wherein the composition for regulating circadian rhythms comprises NQ peptides, C12orf39 genes, NQ peptides cDNA and the like, which relate to circadian regulation in vertebrates as main components.


The present invention relates to an indirubin-3-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell.

Loading Anygen Co. collaborators
Loading Anygen Co. collaborators